This study is in progress, not accepting new patients

Reducing Lung CongestIon Symptoms in Advanced Heart Failure

a study on Heart Failure

Summary

Eligibility
for people ages 18-99 (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around

Description

Summary

The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical outcomes in patients with New York Heart Association (NYHA) functional Class II, Class III, or ambulatory Class IV heart failure (HF), irrespective of left ventricular ejection fraction, who at baseline are treated with guideline-directed drug and device therapies.

Official Title

RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure

Details

This is a prospective, multi-center, 1:1 randomized, patient and observer blinded clinical study, with a Shunt Treatment arm and a non-implant Control arm. A total of approximately 500 patients will be randomized. Patients and all research staff managing the patients after randomization will be blinded during follow-up for a minimum of 12 months to a maximum of 24 months. Control patients will have the opportunity to receive a shunt after 24 months once unblinding occurs, if they provide consent, and continue to meet inclusion/exclusion criteria. All implanted patients will be followed for a total of 5 years from the time of the study device implantation.

Keywords

Heart Failure, V-Wave Interatrial Shunt, Roll in

Eligibility

You can join if…

Open to people ages 18-99

  • Both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) patients
  • NYHA Class II, Class III, or ambulatory Class IV HF
  • Receiving guideline directed medical and device therapy (GDMT) for heart failure
  • For NYHA Class III and ambulatory Class IV, at least one prior hospitalization for heart failure within the last year or elevated BNP level of at least 300 pg/ml or NT-proBNP level of at least 1,500 pg/ml. BNP/NT-ProBNP levels corrected for BMI
  • For NYHA Class II, must have both hospitalization and elevated BNP levels as above specifications

You CAN'T join if...

  • Systolic blood pressure <90 or >160 mmHg
  • Presence of Intracardiac thrombus
  • Pulmonary hypertension with PASP of ≥70 mm/Hg or PVR > 4 WU
  • Significant RV dysfunction - TAPSE <12mm or RVFAC ≤25%
  • Left Ventricular End-Diastolic Diameter (LVEDD) >8cm
  • Moderate to severe aortic or mitral stenosis
  • Stroke or TIA or DVT within the last 6 months
  • eGFR <25 ml/min/1.73 m2
  • Anatomical anomaly on TEE or ICE that precludes implantation of Shunt across fossa ovalis (FO) of the interatrial septum
  • Inadequate vascular access for implantation of shunt, e.g. femoral venous access for transseptal catheterization and inferior vena cava (IVC) is not patent
  • Hemodynamic heart rhythm, or respiratory instability at time of Final Exclusion Criteria

Locations

  • University of California, San Francisco
    San Francisco California 94143 United States
  • The Lundquist Institute (Harbor-UCLA) Medical Center
    Torrance California 90502 United States
  • Kaiser Permanente San Francisco
    San Francisco California 94118 United States
  • Scripps Health
    La Jolla California 92037 United States
  • Cedars Sinai Medical Center
    Los Angeles California 90211 United States
  • Keck Medical Center of USC
    Los Angeles California 90033 United States
  • Long Beach Memorial Medical Center
    Long Beach California 90806 United States
  • Los Robles Hospital & Medical Center
    Thousand Oaks California 91360 United States
  • Stanford Hospital
    Stanford California 94305 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
V-Wave Ltd
ID
NCT03499236
Study Type
Interventional
Participants
About 605 people participating
Last Updated